Hepatitis A, hepatitis B and hepatitis E combination vaccine

Abstract

A combined vaccine for treating hepatitis a, hepatitis b and hepatitis e is characterized in comprising deactivated hepatitis a virus 200-1000 U / mL, recombined hepatitis b virus surface antigen 10-40 mu g / mL, and recombined hepatitis e virus antigen 10-50 mu g / mL.The inventive combined vaccine uses deactivated HAV and recombined HBsAg with good safety and immunogenicigy. Former research has provn that the recombined HEV protein also has good safety and immunogenicigy; and can be used for development of hepatitis e vaccine. The inventive combined vaccine is technologically feasible. The invention can greatly reduce production costs of viral hepatitis vaccine and market price, and improve coverage ratio of vaccine due to the advantages of convenience, multiple effect and low cost.

Description

1. Technical field

[0001] The invention belongs to a combination vaccine and a preparation method thereof, in particular to a hepatitis A-hepatitis B-hepatitis E combination vaccine and a preparation method thereof. 2. Background technology

[0002] Viral hepatitis is an infectious disease mainly caused by liver damage caused by a variety of hepatitis viruses, which is prevalent all over the world. Hepatitis A (HAV) is an acute viral hepatitis caused by the hepatitis A virus (HAV), which is mainly transmitted through the fecal-oral route. In 1988, the acute hepatitis A pandemic was caused by eating cockles in Shanghai, and more than 300,000 cases of hepatitis A occurred; hepatitis B (hepatitis B) is caused by hepatitis B virus (HBV) infection and is widely prevalent in all parts of the world. In endemic areas, the main harm of hepatitis B is that except for fulminant hepatitis, it becomes a chronic virus carrier after infection, and further develops into chronic hepatitis or...